The primary objective of this study was to evaluate the efficacy of MTBF conditioning regimen of salvageable allo-HSCT in patients with relapsed or refractory acute myeloid leukemia. The secondary purpose of the study was to observe the safety of MTBF regimen in these patients.
The subjects voluntarily joined the study, signed the informed consent, had good compliance, and cooperated with the follow-up;
Age 18-65 years old (including upper and lower limits);
No gender limitation
Relapsed or refractory (R/R) acute myeloid leukemia can not achieve complete remission by chemotherapy, and has the indication of salvage allogeneic hematopoietic stem cell transplantation.
Hypersensitivity to any investigational drug or its components;
Uncontrolled systemic diseases (e.g. active infections, uncontrolled hypertension, diabetes, etc.)
Long QTc syndrome or QTc interval>480 ms;
Complete left bundle branch block, II or III degree atrioventricular block;